Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) – Stock analysts at Oppenheimer raised their Q2 2022 earnings estimates for Iovance Biotherapeutics in a report released on Wednesday, April 6th. Oppenheimer analyst M. Breidenbach now forecasts that the biotechnology company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.59). Oppenheimer […]
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) and Gilead Sciences (NASDAQ:GILD – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Earnings & Valuation This table compares Iovance Biotherapeutics and Gilead […]
Equities analysts expect that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) will post earnings of ($0.64) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.73). Iovance Biotherapeutics reported […]
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers
Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting
Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting